Abstract:The epigenome can adequately regulate the on/off states of genes in response to external environmental factors and stress. In recent years, it has been observed that the epigenome, which is modulated through DNA methylation, histone modifications, and chromatin remodeling, changes with age. Alterations in the epigenome lead to the loss of cell-specific epigenome/identity, which in turn triggers a decline in tissue function. In mammals, postnatal epigenomic variations are not only caused by metabolic diseases, such as diabetes or DNA damage, but also by social stress and infectious diseases. Unlike Genome-Wide Association Studies (GWAS), dynamically changing epigenomes, along with their cellular roles, need to be established as objective biomarkers in conjunction with various biological signals, such as walking speed, brain waves, and clinical data. The biological age/aging clock, determined by methylated DNA, has attracted attention, and calorie restriction not only slows the progression of aging, but also seems to suppress it. However, as indicated by gene expression analysis in aging mice, aging is not a linear model, but is represented by nonlinear dynamic changes. Consequently, the development of experimental models and analytical methods that enhance temporal resolution through time-series analysis, tailored to spatial resolution, such as cell distribution and organ specificity, is progressing. Moreover, in recent years, in addition to anti-aging efforts targeting epigenomic variations, global attention has increasingly focused on research and development aimed at rejuvenating treatments, thus leading to the birth of many biotech companies. Aging Hallmarks such as inflammation, stem cells, metabolism, genomic instability, and autophagy, interact closely with the epigenome. Various postnatal and reversible epigenomic controls of aging, including Yamanaka factors (OKSM and OSK), are now entering a new phase. In the future, the development of aging control using diverse modalities, such as mRNA, artificial peptides, and genome editing, is expected, along with an improved molecular understanding of aging and identification of useful biomarkers.

Reversal of epigenetic aging and immunosenescent trends in humans

Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot randomized clinical trial

Chemically induced reprogramming to reverse cellular aging

Epigenetic Reprogramming as a Key to Reverse Ageing and Increase Longevity

Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice

An epigenetic biomarker of aging for lifespan and healthspan

Integrative epigenetics and transcriptomics identify aging genes in human blood

Epigenetic aging: Biological age prediction and informing a mechanistic theory of aging

Multi-omic underpinnings of epigenetic aging and human longevity

When to Trust Epigenetic Clocks: Avoiding False Positives in Aging Interventions.

[Postnatal epigenome-mediated aging control and global trends]

Rejuvant®, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging, after an average of 7 months of use, in the TruAge DNA methylation test

A combination nutritional supplement reduces DNA methylation age only in older adults with a raised epigenetic age

Loss of H3K9 trimethylation leads to premature aging

EPIGENETIC PREDICTORS OF LIFESPAN AND HEALTHSPAN

Epigenetic clock: A promising biomarker and practical tool in aging

Epigenetic measures of ageing predict the prevalence and incidence of leading causes of death and disease burden

Epigenetic Predictor of Age

Transient non-integrative expression of nuclear reprogramming factors promotes multifaceted amelioration of aging in human cells

Development of an epigenetic clock resistant to changes in immune cell composition

Reprogramming to recover youthful epigenetic information and restore vision